CoChat

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose Chemokines influence both tumor progression and anti-tumor immune response. A 32-bp-deletion polymorphism in the chemokine receptor 5 gene (CCR5Delta32) has been shown to result in a non-functional protein. This study was aimed at evaluating the potential impact of this gene polymorphism on disease progression and treatment outcome in patients with melanoma.Patients and methods CCR5 genotyping was performed by PCR on DNA extracted from serum samples of 782 cutaneous melanoma patients with known disease history and long-term clinical follow-up. Genotypes were correlated with patient survival and types of treatment.Results Of 782 melanoma patients, 90 (11.5%) were heterozygous and 12 (1.5%) were homozygous for CCR5Delta32. Analyzing the complete cohort, the disease-specific survival from date of primary diagnosis was not influenced by CCR5 status. Similarly, no significant impact could be detected on the treatment outcome of stage III patients. In 139 stage IV patients receiving immunotherapy, CCR5Delta32 was associated with a decreased survival compared to patients not carrying the deletion (median 12.5 vs. 20.3 months, P = 0.029). Multivariate analysis revealed the CCR5 genotype as an independent factor impacting disease-specific survival in this patient population (P = 0.002), followed by gender (P = 0.019) and pathological classification of the primary (pT; P = 0.022).Conclusion The presence of the CCR5Delta32 polymorphism in patients with stage IV melanoma results in a decreased survival following immunotherapy and may help to select patients less likely to benefit from this type of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00262-007-0407-z

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 88

Metadata

Authors
Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C.
Affiliations
  • University of Würzburg (DE)
  • German Cancer Research Center (DE)
  • Columbia University Irving Medical Center (US)
Corresponding author
Becker, Jürgen C.
Venue
Cancer Immunology, Immunotherapy
Published
2007-10-02
Volume
57
Issue
5
Pages
685-691
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2090347584
Cited by
88
References
24
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 9 · 2012: 9
FWCI
2.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wilhelm Sander-Stiftung
Topics
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
CCR5, metastatic melanoma, immunotherapy, disease-specific survival, chemokine receptors, stage IV melanoma, treatment outcomes, patient selection, chemokines, antitumor immunity
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Polymorphism, Genetic, Skin Neoplasms, Treatment Outcome, Receptors, CCR5, Reverse Transcriptase Polymerase Chain Reaction, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. https://app.cochat.ai/papers/10.1007/s00262-007-0407-z
The paper
Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008). Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-007-0407-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.